Compare FedEx Corporation (FDX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Zimmer Biomet Holdings Inc — how do they compare? FedEx Corporation trades at $325.4 (market cap $76.28B), while Zimmer Biomet Holdings Inc trades at $95.99 (market cap $18.55B). The key difference: FedEx Corporation is far larger — about 4.1× Zimmer Biomet Holdings Inc's market cap, and FedEx Corporation pays the higher dividend (1.51%). Which is the better fit depends on your goals.
| FDX | ZBH | |
|---|---|---|
Market Cap | $76.28B | $18.55B |
Sector | Industrials | Health |
52-Week High | $338.75 | $107.71 |
52-Week Low | $180.51 | $79.58 |
Enterprise Value | $105.91B | $25.61B |
Dividend Yield | 1.51% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $325.53, up 0.14% on the day, with a bullish technical signal and strong analyst backing. Recent earnings beats in Q4 2025 and Q1 2026, with EPS of $5.25 and $6.31 respectively against expectations, highlight operational strength. The company's Network 2.0 initiative aims for $2 billion in annual savings, supporting margin improvement. Valuation ratios like P/E of 17.38 and P/S of 0.81 appear reasonable relative to historical levels.
Outlook is positive with a consensus price target of $360.27, implying 11% upside, driven by cost-cutting and premium revenue shifts. Risks include softer freight demand and debt levels, but institutional buying and bullish sentiment suggest confidence in FedEx's execution amid economic uncertainties.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
